U

Umoja Biopharma

In vivo CAR T-cell cancer therapy

Director Pharmacovigilance

Biology & BiotechUpdated on Nov 11
Full-time$204k - $305k

About the Job

Requirements

  • An advanced degree (PharmD, PhD, MD, or MS) or a health-related degree/certification (PA, RN, or NP), with at least 10 years of pharmacovigilance experience in the biotech or pharmaceutical industry, is required for Director level.
  • Experience supporting clinical-stage programs and working with outsourced pharmacovigilance models is required.
  • Strong working knowledge of global pharmacovigilance regulations, including FDA, EMA, and ICH guidelines, is required.
  • Experience with safety databases and case-processing workflows is required.
  • Familiarity with aggregate reporting and signal detection processes is required.
  • The candidate must be able to work onsite in Seattle at least 2 days per week, or remotely within the US with travel to Seattle at least 5 days per month.
  • Ability to travel as needed is required.
  • Ability to sit for prolonged periods is required.

Responsibilities

  • Oversee case-processing activities, including intake, triage, medical-review support, and expedited reporting.
  • Ensure compliance with global safety-reporting requirements, including FDA, EMA, and ICH guidelines.
  • Manage relationships with pharmacovigilance vendors and contract research organizations, ensuring service quality, timeliness, and data integrity.
  • Support maintenance of safety databases and related systems, including Argus and ArisGlobal.
  • Coordinate with Clinical Development to drive internal cross-functional pharmacovigilance activities.
  • Lead or contribute to preparation of DSURs, PSURs/PBRERs, and IND safety reports.
  • Support safety sections of regulatory submissions and responses to health-authority queries.
  • Contribute to development and maintenance of standard operating procedures and the Pharmacovigilance System Master File.
  • Support signal-detection activities, including data review, trend analysis, and documentation.
  • Participate in safety-review meetings and cross-functional risk discussions.
  • Assist in development and implementation of Risk Management Plans.
  • Partner with Clinical Development on protocol safety design, adverse-event monitoring, and investigator communications.
  • Collaborate with Regulatory Affairs to align on safety-reporting strategy.
  • Support Medical Affairs in communicating safety information as needed.
  • Ensure pharmacovigilance processes are audit- and inspection-ready.
  • Participate in internal audits, vendor audits, and regulatory inspections.
  • Drive continuous-improvement initiatives across pharmacovigilance operations.
  • Manage pharmacovigilance relationships with vendors and contract research organizations; the role may build the pharmacovigilance team and organization in the future.

Desired Qualifications

  • Exposure to regulatory submissions and inspections is preferred.
  • Experience in oncology, cell therapy, or gene therapy is preferred.

About the Company

Umoja Biopharma

In vivo CAR T-cell cancer therapy

Umoja Biopharma develops immunotherapies that reprogram patients’ T cells inside the body (in vivo) to attack cancer. Its main product approach is a CAR T-cell gene therapy platform designed to be produced in-house and sold as off-the-shelf regimens, enabling scalable treatment for both solid tumors and blood cancers that have not responded to other therapies. The treatment works by modifying the patient’s immune system directly in the body to create CAR T cells that can target and kill cancer cells, aiming for lasting remissions. Unlike many therapies that extract cells from a patient, modify them outside the body, and then reinsert them, Umoja Biopharma focuses on in-body cell reprogramming and in-house manufacturing to streamline delivery. The company differentiates itself through its in vivo, off-the-shelf CAR T approach and its goal of broad applicability across cancer stages, seeking to provide accessible, scalable cancer treatments across solid and hematologic cancers.

Company size
201-500
Company stage
Series C
Total funding
$363M
Headquarters
Seattle, WA
Founded
2019

Recently Posted Jobs

Explore more opportunities at Umoja Biopharma

See more jobs